Ron Cooper

President and Chief Executive Officer

Ron Cooper, Albireo’s first President and CEO, is a global P&L leader with a track record of growing businesses, brands and organizations in the U.S. and Europe. For over 25 years, Ron worked in five different countries and held positions of increasing responsibility in sales, marketing and general management with Bristol-Myers Squibb, culminating in his role as President of Europe where he was responsible for over 30 countries with sales exceeding $4.5 billion.

While at BMS, Ron played a leadership role in several product successes, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz® Sustiva® Sprycel® and Yervoy®. Ron has successfully completed more than a dozen business development deals, including the creation of the first single tablet HIV/AIDS regimen partnership. He is a graduate of St. Francis Xavier University in Canada.

Team members

David Chiswell, Ph.D. – Chairman

Former CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP

Anne Klibanski, M.D.

President and CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics

Stephanie S. Okey, M.S.

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Davey S. Scoon

Former CFO, Tom’s of Maine; Board of Trustees, Allianz Global Investors

Ron Cooper

President and Chief Executive Officer